Payment overview · 2025
General Payments
$192.03
7 reported records · 6 companies
Healthcare provider profile · identity verified
Tara Thompson, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HENDERSON, NV · NPI 1568161651
Verified facts
What the public records show
CMS Open Payments records show Tara Thompson, NP received $192.03 in general payments during 2025 across 7 reported records.
Medtronic, Inc. accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$72.81 | 37.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.56 | 15.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.22 | 12.6% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $23.78 | 12.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.73 | 12.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.93 | 8.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $192.03 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MAZOR X SYSTEM Normalized: mazor x system |
Device | Medtronic, Inc. | $72.81 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.56 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.56 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 504 | 165 |
| Lisinopril | Lisinopril | 300 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 298 | 99 |
| Losartan Potassium | Losartan Potassium | 270 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 213 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 202 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 179 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 151 | 63 |
| Metformin Hcl | Metformin Hcl | 146 | 55 |
| Gabapentin | Gabapentin | 142 | 54 |
| Omeprazole | Omeprazole | 140 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 40 |
| Alendronate Sodium | Alendronate Sodium | 105 | 39 |
| Simvastatin | Simvastatin | 96 | 29 |
| Carvedilol | Carvedilol | 92 | 25 |
| Metformin Hcl Er | Metformin Hcl | 92 | 29 |
| Tramadol Hcl | Tramadol Hcl | 92 | 17 |
| Trazodone Hcl | Trazodone Hcl | 88 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 30 |
| Furosemide | Furosemide | 69 | 30 |
| Montelukast Sodium | Montelukast Sodium | 69 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 23 |
| Jardiance | Empagliflozin | 66 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 18 |
| Potassium Chloride | Potassium Chloride | 57 | 19 |
| Bupropion Xl | Bupropion Hcl | 56 | 18 |
| Allopurinol | Allopurinol | 55 | 18 |
| Ozempic | Semaglutide | 55 | 15 |
| Meloxicam | Meloxicam | 49 | 18 |
| Mounjaro | Tirzepatide | 49 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 26 |
| Baclofen | Baclofen | 46 | 20 |
| Sertraline Hcl | Sertraline Hcl | 44 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Azithromycin | Azithromycin | 41 | 37 |
| Prednisone | Prednisone | 41 | 34 |
| Famotidine | Famotidine | 40 | 18 |
| Pregabalin | Pregabalin | 38 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 14 |
| Methylprednisolone | Methylprednisolone | 33 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 14 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 13 |
| Meclizine Hcl | Meclizine Hcl | 30 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Eliquis | Apixaban | 29 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | 11 |
| Lorazepam | Lorazepam | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | 11 |
| Finasteride | Finasteride | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | 12 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 16 |
| Trulicity | Dulaglutide | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 11 |
| Naproxen | Naproxen | 24 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Dayvigo | Lemborexant | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $192.03 · 7 records | Medtronic, Inc. | ABRYSVO, AREXVY, COMIRNATY, Cologuard Collection Kit, MAZOR X SYSTEM, PREVNAR 20, REBLOZYL, SHINGRIX, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Celgene Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error